qtr-four earnings per share $num-two.
qtr-four adjusted earnings per share $num-two.
qtr-four adjusted earnings per share $num-one.
qtr-four revenue $num-one billion.
qtr-four revenue $num-one billion.
qtr-four revenue $num-two billion.
labcorp- full-year year-seven guidance: adjusted earnings per share of $num-one to $num-two and free cash flow of $num-four billion to $num-five billion.
labcorp - longer-term outlook (year-seven-year-nine): base business organic revenue compound annual growth of num-one%-num-two% versus year-six.
labcorp - longer-term outlook (year-seven-year-nine) base business average annual margin expansion of num-one bps to num-two bps versus year-six.
labcorp - longer-term outlook (year-seven-year-nine) adjusted earnings per share compound annual growth of num-one%-num-two% versus year-four.
labcorp sees fy year-seven total labcorp enterprise revenue down 6.5% to down num-one%.
labcorp sees fy year-seven total drug development revenue up 7.0% to up num-two%.